The IRA reset lands on semaglutide, not resmetirom — and Rezdiffra is the rare launch priced inside its own ICER value range.
The intuitive read, that a small molecule faces an earlier Medicare negotiation clock than a biologic, is directionally true (small molecules become negotiation-eligible roughly 7-9 years post-approval versus 11-13 for biologics; KFF), but the near-term reality runs the other way. Semaglutide (the Ozempic / Rybelsus / Wegovy franchise) was selected for Medicare Drug Price Negotiation in IPAY 2027; CMS published negotiated prices on November 30, 2025, effective January 1, 2027, and the negotiated price applies across the franchise, including Wegovy, the MASH-labeled brand. Resmetirom (Rezdiffra) appears on no CMS selected-drug list (IPAY 2026, 2027, or 2028): approved only in March 2024, it has not reached the negotiation-eligibility window. So the first IRA-driven price reset in US MASH hits the GLP-1, not the THR-β agent.
On value, resmetirom carries an unusually clean HTA record. ICER's NASH assessment found the evidence adequate to demonstrate a net health benefit for resmetirom versus lifestyle management for noncirrhotic F2-F3 MASH (Midwest CEPAC panel vote 8-7), and set a health-benefit price range of $39,600-$50,100 per year (ICER Final Evidence Report, updated January 10, 2025). Rezdiffra's ~$47,400 annual WAC sits inside that range — a rare case of a launch priced within its own cost-effectiveness benchmark, and a materially stronger value narrative than the payer would assume. Both agents route to Medicare Part D (Rezdiffra oral; semaglutide self-administered subcutaneous injection), so the access contest plays out on formulary tier, prior authorization, and step edits rather than Part B site-of-care economics.
US MASH agent payer status — IRA, ICER, and price versus value
| Drug (Brand / INN) — Company | Benefit Routing | IRA Status | ICER Verdict | Annual price | Commercial PA / access |
|---|---|---|---|---|---|
| Rezdiffra (resmetirom) — MadrigalThe rare launch priced within its own cost-effectiveness benchmark. Single-indication and liver-specific — easy for a P&T committee to wall off to the diagnosed F2-F3 pool. | Medicare Part D (oral, once-daily) | On no CMS selected-drug list (IPAY 2026-2028); small molecule approved Mar 2024, not yet negotiation-eligible | Net health benefit adequate (Midwest CEPAC 8-7); value price $39,600-$50,100/yr | ~$47,400 WAC — inside the ICER value range | PA to noncirrhotic F2-F3 via FIB-4/elastography; specialty tier |
| Wegovy (semaglutide 2.4 mg) — Novo NordiskThe IRA reset lands on the GLP-1 first — semaglutide was selected on Ozempic's diabetes Part D spend, and the negotiated price applies across the franchise, including Wegovy. | Medicare Part D (self-administered SC injection) | Semaglutide franchise SELECTED for IPAY 2027; negotiated price effective Jan 1, 2027 | Not separately assessed for MASH by ICER | Ozempic $959→$274/mo; Wegovy $385/mo (IPAY 2027 negotiated, higher doses) | Aggressive GLP-1 UM: PA, step edits, obesity/diabetes spillover exposure |
Sources: CMS Medicare Drug Price Negotiation selected-drug lists: IPAY 2027 (semaglutide selected; negotiated prices published Nov 30, 2025, effective Jan 1, 2027) and IPAY 2026/2028 (resmetirom not selected); ICER Final Evidence Report, Resmetirom and Obeticholic Acid for NASH (updated Jan 10, 2025) and Midwest CEPAC summary, JMCP 2023;29(10):1169; Rezdiffra WAC ~$47,400/yr per Madrigal price-transparency filings and managed-care pricing reporting; KFF (IRA small-molecule vs biologic negotiation horizon). WAC and franchise list prices are non-PubMed and labeled as such.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Resmetirom's absence from every CMS selected-drug list (IPAY 2026-2028)
- the small-molecule eligibility window
- and the contrast with semaglutide's IPAY 2027 selection and January 2027 negotiated-price reset across the franchise
Delivers
- ICER's NASH net-health-benefit verdict (Midwest CEPAC 8-7), the $39,600-$50,100/yr value range, and the WAC-vs-value analysis showing the ~$47,400 list price landing inside the range
Delivers
- Part D routing for both agents
- the aggressive PA / step-edit / exclusion posture aimed at GLP-1s because of obesity/diabetes spillover
- and the single-indication wall-off advantage for a liver-specific oral agent
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- How Rezdiffra (oral) and Wegovy (self-administered SC injection) both route to Medicare Part D rather than Part B
- Why the access contest plays out on formulary tier, prior authorization, and step edits rather than site-of-care economics
- Semaglutide's IPAY 2027 selection, with CMS negotiated prices published November 30, 2025, effective January 1, 2027 across the Ozempic/Rybelsus/Wegovy franchise
- Why resmetirom appears on no CMS selected-drug list (IPAY 2026-2028), having been approved only in March 2024
- The structural timing gap: small molecules become negotiation-eligible roughly 7-9 years post-approval versus 11-13 years for biologics (KFF)
- Why Rezdiffra's March 2024 approval keeps it outside the negotiation-eligibility window through at least IPAY 2028
- The Midwest CEPAC's 8-7 vote that resmetirom's evidence demonstrates net health benefit versus lifestyle management in noncirrhotic F2-F3 MASH
- ICER's $39,600-$50,100 per year health-benefit price range, set in the Final Evidence Report updated January 10, 2025
- Rezdiffra's ~$47,400 annual WAC sitting inside ICER's own $39,600-$50,100 cost-effectiveness benchmark
- Why a launch priced within its own value range gives Madrigal a stronger negotiating position with payers than assumed
- PA to the noncirrhotic F2-F3 population via FIB-4 or elastography confirmation, and specialty-tier placement for resmetirom
- The aggressive GLP-1 utilization management (PA, step edits, obesity/diabetes spillover exposure) applied to Wegovy
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
MASH P&HTA is built from CMS IRA negotiation documentation, ICER evidence reports, drug price-transparency disclosures, and Medicare benefit-design specifications. Every payer claim is verified against its authoritative source before inclusion.
Key sources: CMS Medicare Drug Price Negotiation selected-drug lists (IPAY 2026-2028); ICER Final Evidence Report, Resmetirom and Obeticholic Acid for NASH (updated January 10, 2025) and the Midwest CEPAC summary (JMCP 2023;29(10):1169); Rezdiffra WAC per Madrigal price-transparency filings; KFF analysis of IRA small-molecule vs biologic negotiation timelines.
- IRA — semaglutide (Ozempic / Rybelsus / Wegovy) selected for Medicare Drug Price Negotiation IPAY 2027; negotiated prices published Nov 30, 2025, effective Jan 1, 2027 (Ozempic $959→$274/mo; Wegovy higher-dose negotiated $385/mo) (CMS selected-drug list IPAY 2027).
- IRA — resmetirom (Rezdiffra) is on no CMS selected-drug list (IPAY 2026, 2027, or 2028); as a small molecule approved March 2024 it has not reached the negotiation-eligibility window (CMS selected-drug lists IPAY 2026-2028).
- IRA structural horizon — small molecules become negotiation-eligible roughly 7-9 years post-approval versus 11-13 years for biologics; Part D negotiated prices from 2026 and the Part D $2,000 out-of-pocket cap from 2025 (KFF).
- ICER — the NASH assessment found the evidence adequate to demonstrate a net health benefit for resmetirom vs lifestyle management for noncirrhotic F2-F3 MASH (Midwest CEPAC vote 8-7); ICER's health-benefit price range is $39,600-$50,100/yr (ICER Final Evidence Report, updated Jan 10, 2025; Midwest CEPAC summary, JMCP 2023;29(10):1169).
- Pricing — Rezdiffra WAC is ~$47,400/yr, inside ICER's $39,600-$50,100 cost-effective range (Madrigal price-transparency filings; managed-care pricing reporting) [non-PubMed, labeled].
- Benefit routing — Rezdiffra (oral) and semaglutide (self-administered subcutaneous injection) both route to Medicare Part D, not Part B (CMS Part B vs Part D classification).
Frequently asked questions
Commission this assessment
AXLRx MASH Payer & HTA is built for market access, HEOR, and pricing teams navigating IRA exposure, ICER's value verdict, and the Part D access dynamics of the US MASH market. Custom assessment in 72 hours.
Specify indication, payer focus (IRA/ICER, PA criteria), and commercial question.
AXLRx analyst confirms payer scope, IRA/ICER analysis, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.